Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + penpulimab + chemotherapy as first-line treatment for extensive-stage small cell lung cancer
ChiCTR2100053228Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Dec 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib, penpulimab and etoposide in small cell lung cancer (SCLC), sponsored by Chinese PLA General Hospital. Primary endpoints: recommended phase II dose and progression-free survival. Started Dec 2021; status: recruiting.
02
Drugs
anlotinibpenpulimabetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2100053228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053228.